Patents by Inventor Aya Sakamoto

Aya Sakamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ROS (REACTIVE OXYGEN SPECIES) PRODUCTION ENHANCING AGENT
    Publication number: 20240352142
    Abstract: It is an object of the present invention to provide an ROS production-enhancing agent. According to the present invention, an ROS production-enhancing agent, comprising a substance that recognizes a transferrin receptor, is provided.
    Type: Application
    Filed: August 26, 2022
    Publication date: October 24, 2024
    Applicant: PERSEUS PROTEOMICS INC.
    Inventors: Keiko KATSUMI, Junpei OYA, Keisuke ISHII, Aya SAKAMOTO
  • METHOD FOR DETERMINING MEDICINAL EFFECT OR SENSITIVITY OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY
    Publication number: 20240288453
    Abstract: It is an object of the present invention to provide a method for determining the medicinal effect or sensitivity of an anti-transferrin receptor antibody. According to the present invention, provided is a method for determining the medicinal effect or sensitivity of an anti-human transferrin receptor antibody having an action to inhibit the binding between human transferrin and a human transferrin receptor, wherein the method uses an intracellular iron content as an indicator.
    Type: Application
    Filed: October 8, 2021
    Publication date: August 29, 2024
    Applicants: National University Corporation Tokai National Higher Education and Research System, PERSEUS PROTEOMICS INC.
    Inventors: Hitoshi KIYOI, Yuichi ISHIKAWA, Marie NAKASHIMA, Yuta OHIRA, Junpei OYA, Fumiko NOMURA, Keiko KATSUMI, Aya SAKAMOTO, Yoshinori UKAI, Tadashi MATSUURA
  • Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
    Patent number: 9017683
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: April 28, 2015
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishii, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa
  • HIGHLY EFFECTIVE ANTI-CADHERIN ANTIBODY FOR INDUCTION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY IN VIVO
    Publication number: 20130245232
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Application
    Filed: May 3, 2013
    Publication date: September 19, 2013
    Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki ABURATANI, Lilin ZHANG, Keisuke ISHII, Katsushi KOUDA, Aya SAKAMOTO, Keiko KATSUMI, Hiroshi ONISHI, Yoko KAYUKAWA
  • HIGHLY EFFECTIVE ANTI-CADHERIN ANTIBODY FOR INDUCTION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY IN VIVO
    Publication number: 20130243771
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Application
    Filed: May 3, 2013
    Publication date: September 19, 2013
    Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki ABURATANI, Lilin ZHANG, Keisuke ISHII, Katsushi KOUDA, Aya SAKAMOTO, Keiko KATSUMI, Hiroshi ONISHI, Yoko KAYUKAWA
  • Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
    Patent number: 8455249
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: June 4, 2013
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishii, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa
  • ANTI-CADHERIN ANTIBODY
    Publication number: 20120136140
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Application
    Filed: April 30, 2010
    Publication date: May 31, 2012
    Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishi, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa